Policy & Regulation
Health Canada grants approval to Merck's KEYTRUDA for first-line treatment of gastric cancer
19 April 2024 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Friday Health Canada's approval of KEYTRUDA (pembrolizumab) in combin...
YS Biopharma's YS-HBV-002 receives Philippine clinical trial approval
19 April 2024 - YS Biopharma Co., Ltd. (Nasdaq: YS), a China-based global biopharmaceutical company, announced on Thursday that it has received clinical trial approval from the Philippine Food and Dru...
Anixa Biosciences adds Dr Sanjay Juneja to Cancer Business Advisory Board
19 April 2024 - Anixa Biosciences, Inc. (NASDAQ: ANIX), a California-based clinical-stage biotechnology company, announced on Thursday that it has added Sanjay Juneja, MD to its Cancer Business Adviso...
EMA grants orphan drug designation to Moleculin's Annamycin for AML
18 April 2024 - Clinical stage pharmaceutical company Moleculin Biotech Inc (Nasdaq:MBRX) announced on Thursday that Annamycin, its next-generation anthracycline, has received orphan drug designation ...
Aspen Neuroscience doses first subject in ASPIRO trial of ANPD001
18 April 2024 - Aspen Neuroscience, Inc., a United States-based clinical development-stage, private company, announced on Wednesday that it has dosed its first subject in the ASPIRO trial, a Phase 1/2...
Sage Therapeutics reports dalzanemdor failed to meet primary endpoint in Parkinson's disease trial
17 April 2024 - Biopharmaceutical company Sage Therapeutics Inc (Nasdaq:SAGE) on Wednesday revealed topline results from the PRECEDENT study, showing that dalzanemdor (SAGE-718) did not achieve statis...